Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors
Sponsor: National Cancer Institute (NCI)
A observational or N/A phase clinical study on Central Nervous System Neoplasm, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Aug 2018 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Aug 2018 [monthly]
Completed
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Completed NA
Phase: EARLY_PHASE1 → NA
-
Feb 2017 — Sep 2017 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Wake Forest University Health Sciences
For direct contact, visit the study record on ClinicalTrials.gov .